LAMEA Fusion Biopsy Market Size

LAMEA Fusion Biopsy Market Size & Top Market Players 2026

LAMEA Fusion Biopsy Market By End Use (Diagnostic centers, Hospitals and Ambulatory care centers), By Route (Transperineal and Transrectal), By Country, Industry Analysis and Forecast, 2020 - 2026

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Published Date : September-2020 | Number of Pages : 60 | Format : PDF

COVID-19

Get in-depth analysis of the COVID-19 impact on the LAMEA Fusion Biopsy Market

Market Report Description

The Latin America, Middle East and Africa Fusion Biopsy Market would witness market growth of 12.3% CAGR during the forecast period (2020-2026). The growing incidence of prostate cancer, increasing adoption of multiparametric MRI in prostate cancer treatment and care along with greater specificity of fusion biopsy are some of the factors that are expected to drive the targeted MR/Ultrasound biopsy system demand in the coming years. According to several studies, the success rate of prostate biopsy combined with traditional core biopsy is about 33%, while the MR/US fusion biopsy has the success rate ranging from 58-70%. Thus, the need for a repeat biopsy is eliminated by fusion biopsy and therefore minimizes additional healthcare costs and patient discomfort.

At times, it is hard to detect prostate cancer and fusion biopsy is very beneficial in this. The Fusion Biopsy System Market is likely to grow globally at a significant CAGR in the forecast period because of the fact that the scope, product types, and applications of these products are continuously increasing across the globe. A Fusion biopsy system combines MRI ultrasound along with biopsy system for a better view. Fusion biopsy is also termed as fusion guided biopsy. Moreover, biopsy infers taking the tissue sample from the body then examines the report and detect it in the best possible manner. When test previously done in case of any prostrate related problems and if that test shows an anomaly in certain areas of the sample; then doctors recommend for biopsy.

Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: Fusion Biopsy Market in LAMEA is expected to register a CAGR of 12.3% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.

Scope of the LAMEA Fusion Biopsy Market Analysis

Market Segmentation:

By End Use

  • Diagnostic centers
  • Hospitals
  • Ambulatory care centers

By Route

  • Transperineal
  • Transrectal

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Koninklijke Philips N.V.
  • Hitachi, Ltd.
  • Baxter International, Inc. (MedCom)
  • Esaote SpA
  • Eigen
  • KOELIS, Inc.
  • Focal Healthcare, Inc.
  • UC-Care Medical Systems Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Fusion Biopsy Market Related Reports:

Global Market

North America Market

Europe Market

Asia Pacific Market

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities